Canaccord Genuity Maintains Buy on Aptose Biosciences, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Aptose Biosciences (NASDAQ:APTO) but lowers the price target from $15 to $6.
May 16, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity analyst John Newman maintains a Buy rating on Aptose Biosciences but lowers the price target from $15 to $6.
The Buy rating suggests continued confidence in the company's long-term prospects, but the significant reduction in the price target indicates a reassessment of short-term valuation. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100